Groupe Hospitalier Rance Emeraude — Clinical Trial Site

41 Registered trials

25 Currently recruiting

Organisation

Groupe Hospitalier Rance Emeraude

Location

Saint-Malo Cedex, France

Identifier

ORG-100043211

Address

1 Rue De La Marne, 35403, France

Departments

35400
93125006:Oncologie
Digestive oncology
gastroenterology
GI
hematology
Hépato-gastoentérologie
Hépato-Gastro-Entérologie
hepato-gastro-enterology
hépato-gastroentérologie
Hepato-gastroenterology
hépato/digestive oncology
Hepatogastroenterology
N
Nephrology
Onco-hématologie
Oncologie
Oncologie digestive
ONCOLOGIE MEDICALE
Oncology
oncology department
Radiotherapy
Respiratory Diseases
Rhumatologie
Service d'Hépato-gastro-entérologie
service d'oncologie
Service des Maladies Infectieuses et Respiratoires
Unité de surveillance continue-Réanimation

Clinical trials at this site (41)

Search interface

Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite inst… Recruiting

2023-506102-39-00 metastatic gastric cancer 4 2023-12-18
THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting

2022-501494-39-00 Uncontrolled Hypertension IN patients with moderate to 5 2023-03-28
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for… Recruiting

2024-511904-18-00 Pancreatic adenocarcinoma (PAC) 10 2020-07-08
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended

2022-501027-25-01 Multiple Sclerosis 11 2023-06-01
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended

2024-512269-14-00 GIant cell Arteritis 5 2020-01-27
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended

2024-512470-10-00 End-stage Renal disease 11 2018-02-02
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended

2024-516299-13-00 Resectable Gastric Cancer 4 2024-09-06
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4